The effect of colesevelam hydrochloride on Insulin sensitivity and secretion in patients with type 2 diabetes: A pilot study

Metabolic Syndrome and Related Disorders

Volumn 8, Issue 2, 2010, Pages 179-187

  Schwartz, Sherwyn L ^a   Lai, Yu Ling ^b   Xu, Jianbo ^b   Abby, Stacey L ^b   Misir, Soamnauth ^b   Jones, Michael R ^b   Nagendran, Sukumar ^b  

^a Diabetes and Glandular Disease Clinic   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESEVELAM; GLUCOSE; INSULIN; PLACEBO;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ALGORITHMS; ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; POSTPRANDIAL PERIOD;

EID: 77950620903     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2009.0049     Document Type: Article

References (28)

1. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008;168:1975-1983.
2. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-1484.
3. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Effi cacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-1540.
4. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results from the Glucose Lowering effect of WelChol Study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74-83.
5. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009;32(Suppl 1):S13-S61.
6. Guillausseau PJ, Meas T, Virally M, Laloi-Michelin M, Medeau V, Kevorkian JP. Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab 2008;34(Suppl 2):S43-S48. (Pubitemid 351982036)
7. Bavenholm PN, Pigon J, Ostenson CG, Efendic S. Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance. Diabetes 2001;50:1449-1454.
8. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223.
9. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008;294:E15-E26.
10. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470.
11. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385-411.
12. Kuipers F, Murphy EJ. Effects of colesevelam HCl on bile acid kinetics. Available at: http://www.clinicaltrials.gov/ct2/ show/NCT00476710?term= colesevelam+HCl&rank=8/. Accessed August 18, 2009.
13. Vella A. The effect of colesevelam hydrochloride (HCl) on disposition index and incretin concentrations in subjects with type 2 diabetes. Available at: http://www.clinicaltrials.gov/ct2/ show/study/NCT00951899?term= colesevelam+HCl&recr=Op en&rank=2/. Accessed August 18, 2009.
14. Goldfi ne AB. Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Curr Opin Cardiol 2008;23:502-511.
15. Mitro N, Mak PA, Vargas L, Godio C, Hampton E, et al. The nuclear receptor LXR is a glucose sensor. Nature 2007;445:219-223.
16. Suzuki T, Oba K, Igari Y, Matsumura N, Watanabe K, et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 2007;74:338-343.
17. Forman BM, Lin M, Jones MR, Abby SL, Van Citters G. Colesevelam HCl Affects Gene Expression in Metabolic Tissues in db/db Mice. American Diabetes Association 68th Scientific Sessions, San Francisco, CA, 2008.
18. Beysen C, Deines K, Tsang E, Murphy E, Chan M, et al. Colesevelam HCl reduces fasting plasma glucose concentrations by improving plasma glucose clearance in subjects with type 2 diabetes. 45th Annual Meeting of the European Association for the Study of Diabetes, Vienna, Austria, 2009.
19. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study. Curr Med Res Opin 2008;24:2943-2952.
20. Vella A, Shah P, Basu R, Basu A, Camilleri M, et al. Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes. Diabetes 2001;50:565-572.
21. Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, et al. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab 2008;295:E779-E784.
22. Poley JR, Hofmann AF. Role of fat maldigestion in pathogenesis of steatorrhea in ileal resection. Fat digestion after two sequential test meals with and without cholestyramine. Gastroenterology 1976;71:38-44.
23. Hoffman NE, Hofmann AF. A comparison of the rate of absorption micellar and nonmicellar oleic acid. A jejunal perfusion study in man. Am J Dig Dis 1973;18:489-492.
24. Knoebel LK. Intestinal absorption in vivo of micellar and nonmicellar lipid. Am J Physiol 1972;223:255-261.
25. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009;8:369-385.
26. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008;57:2280-2287.
27. Brufau G, Kuipers F, Prado K, Abby SL, Jones MR, et al. Altered bile salt metabolism in type 2 diabetes mellitus (T2DM). American Diabetes Association 68th Scientific Sessions, San Francisco, CA, 2008.
28. Carulli N, Bertolotti M, Carubbi F, Concari M, Martella P, et al. Review article: Effect of bile salt pool composition on hepatic and biliary functions. Aliment Pharmacol Ther 2000;14(Suppl 2):14-18.